Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
复制标题
DOI：
10.1016/j.annonc.2021.08.1752
复制
发表时间：
2021-11-20
影响因子：
50.5
通讯作者：
Pentheroudakis, G.
中科院分区：
文献类型：
--
作者：
Yoshino, T.;Argiles, G.;Pentheroudakis, G.
欧洲肿瘤医学学会（ESMO）关于局部结肠癌的诊断、治疗和随访的临床实践指南的最新版本于2020年发布。ESMO和日本肿瘤医学学会（JSMO）决定于2021年3月召开一次特别的虚拟指南会议，以调整ESMO 2020指南，以考虑与亚洲患者局部结肠癌治疗相关的种族差异。这些指南代表了代表日本（JSMO）、中国（CSCO）、印度（ISMPO）、韩国（KSMO）、马来西亚（MOS）、新加坡（SSO）和台湾（TOS）肿瘤学会的局部结肠癌患者治疗专家达成的共识意见。投票以科学证据为基础，独立于不同亚洲国家目前的治疗做法、药物供应和报销情况。
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries.